Study Finds Weight-Loss Drugs from Novo Nordisk (NVO) and Eli Lilly (LLY) Effective at Lower Doses
A recent study found that lower doses of GLP-1 weight-loss drugs from Novo Nordisk A/S (NYSE:NVO) and Eli Lilly and Company (NYSE:LLY) still result in measurable weight loss, though significantly less than higher recommended dosages. Patients on low-dose tirzepatide lost an average of 5.5% body weight over a year compared to 20.2% at full doses, while those taking semaglutide saw similar trends with 2.2% versus 13.7%. The findings suggest that lower dosages may help more patients stay on treatment due to reduced side effects like nausea and better tolerability. The results could support broader adoption of both drugs among cost-conscious or sensitive patient populations, potentially expanding the overall user base for these medications. However, if many remain at low doses, revenue per patient might be affected as weight loss is less pronounced compared to higher dosages. Eli Lilly's tirzepatide showed stronger performance in lower-dose scenarios than Novo Nordisk’s semaglutide, reinforcing its competitive edge despite ongoing challenges from Novo's oral obesity treatments and pipeline advancements. The study also highlights the trade-off between efficacy and tolerability—while low doses reduce nausea, they increase risks of other side effects like constipation or muscle cramps. This could influence prescribing decisions as competition in the expanding $100 billion annual obesity drug market intensifies.
Topics: Eli Lilly GLP-1 drugs Novo Nordisk semaglutide tirzepatide weight loss